Key Takeaways Novartis will acquire Tourmaline Bio for $1.4B, paying$48 per share in cash to shareholders. The deal adds pacibekitug, an anti-IL-6 mAb targeting ASCVD, to Novartis' pipeline,Phase II data showed pacibekitug cut hs-CRP levels by up to 86% with placebo-like safety.Novartis ((NVS) has announced that it will acquire Tourmaline Bio, Inc. ((TRML), a New York-based, publicly traded clinical-stage biopharmaceutical company, for $1.4 billion.The acquisition will add phase III ready candidate pacibek ...